vs
FMC CORP（FMC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
FMC CORP的季度营收约是Royalty Pharma plc的1.2倍（$759.0M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs -37.0%，领先71.5%），Royalty Pharma plc同比增速更快（4.8% vs -4.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -14.5%）
FMC公司是总部位于美国宾夕法尼亚州费城的化工制造企业，1883年创立之初以生产杀虫剂为主，后续逐步拓展业务至其他领域。二战期间曾为美国陆军部设计生产两栖履带登陆车，目前在全球拥有7000名员工，业务布局广泛。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FMC vs RPRX — 直观对比
营收规模更大
FMC
是对方的1.2倍
$622.0M
营收增速更快
RPRX
高出8.8%
-4.0%
净利率更高
RPRX
高出71.5%
-37.0%
两年增速更快
RPRX
近两年复合增速
-14.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $759.0M | $622.0M |
| 净利润 | $-281.2M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | -10.6% | 62.4% |
| 净利率 | -37.0% | 34.4% |
| 营收同比 | -4.0% | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | $-2.25 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FMCRPRX
| Q1 26 | $759.0M | — | ||
| Q4 25 | $1.1B | $622.0M | ||
| Q3 25 | $542.2M | $609.3M | ||
| Q2 25 | $1.1B | $578.7M | ||
| Q1 25 | $791.4M | $568.2M | ||
| Q4 24 | $1.2B | $593.6M | ||
| Q3 24 | $1.1B | $564.7M | ||
| Q2 24 | $1.0B | $537.3M |
净利润FMCRPRX
| Q1 26 | $-281.2M | — | ||
| Q4 25 | $-1.7B | $214.2M | ||
| Q3 25 | $-569.3M | $288.2M | ||
| Q2 25 | $66.7M | $30.2M | ||
| Q1 25 | $-15.5M | $238.3M | ||
| Q4 24 | $-16.3M | $208.2M | ||
| Q3 24 | $65.0M | $544.0M | ||
| Q2 24 | $295.1M | $102.0M |
毛利率FMCRPRX
| Q1 26 | — | — | ||
| Q4 25 | 39.8% | — | ||
| Q3 25 | 23.8% | — | ||
| Q2 25 | 38.7% | — | ||
| Q1 25 | 40.0% | — | ||
| Q4 24 | 42.9% | — | ||
| Q3 24 | 36.3% | — | ||
| Q2 24 | 38.3% | — |
营业利润率FMCRPRX
| Q1 26 | -10.6% | — | ||
| Q4 25 | -130.8% | 62.4% | ||
| Q3 25 | -73.1% | 70.1% | ||
| Q2 25 | 12.0% | 36.3% | ||
| Q1 25 | 7.4% | 94.0% | ||
| Q4 24 | 19.2% | 60.9% | ||
| Q3 24 | 12.7% | — | ||
| Q2 24 | 6.0% | 50.2% |
净利率FMCRPRX
| Q1 26 | -37.0% | — | ||
| Q4 25 | -158.8% | 34.4% | ||
| Q3 25 | -105.0% | 47.3% | ||
| Q2 25 | 6.3% | 5.2% | ||
| Q1 25 | -2.0% | 41.9% | ||
| Q4 24 | -1.3% | 35.1% | ||
| Q3 24 | 6.1% | 96.3% | ||
| Q2 24 | 28.4% | 19.0% |
每股收益（稀释后）FMCRPRX
| Q1 26 | $-2.25 | — | ||
| Q4 25 | $-13.77 | $0.49 | ||
| Q3 25 | $-4.52 | $0.67 | ||
| Q2 25 | $0.53 | $0.07 | ||
| Q1 25 | $-0.12 | $0.55 | ||
| Q4 24 | $-0.13 | $0.46 | ||
| Q3 24 | $0.52 | $1.21 | ||
| Q2 24 | $2.35 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $390.9M | $618.7M |
| 总债务越低越好 | $2.8B | $9.0B |
| 股东权益账面价值 | $1.8B | $9.7B |
| 总资产 | $9.4B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.50× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FMCRPRX
| Q1 26 | $390.9M | — | ||
| Q4 25 | $584.5M | $618.7M | ||
| Q3 25 | $497.7M | $938.9M | ||
| Q2 25 | $438.2M | $631.9M | ||
| Q1 25 | $315.3M | $1.1B | ||
| Q4 24 | $357.3M | $929.0M | ||
| Q3 24 | $416.7M | $950.1M | ||
| Q2 24 | $471.5M | $1.8B |
总债务FMCRPRX
| Q1 26 | $2.8B | — | ||
| Q4 25 | $3.4B | $9.0B | ||
| Q3 25 | $3.4B | $8.9B | ||
| Q2 25 | $3.4B | $8.0B | ||
| Q1 25 | $3.1B | $7.6B | ||
| Q4 24 | $3.1B | $7.6B | ||
| Q3 24 | $3.1B | $7.6B | ||
| Q2 24 | $3.1B | $7.6B |
股东权益FMCRPRX
| Q1 26 | $1.8B | — | ||
| Q4 25 | $2.1B | $9.7B | ||
| Q3 25 | $3.8B | $9.6B | ||
| Q2 25 | $4.4B | $9.5B | ||
| Q1 25 | $4.4B | $9.8B | ||
| Q4 24 | $4.5B | $10.3B | ||
| Q3 24 | $4.6B | $10.3B | ||
| Q2 24 | $4.6B | $9.8B |
总资产FMCRPRX
| Q1 26 | $9.4B | — | ||
| Q4 25 | $9.7B | $19.6B | ||
| Q3 25 | $12.1B | $19.3B | ||
| Q2 25 | $12.3B | $18.3B | ||
| Q1 25 | $11.8B | $17.6B | ||
| Q4 24 | $11.7B | $18.2B | ||
| Q3 24 | $12.2B | $18.0B | ||
| Q2 24 | $12.1B | $17.7B |
负债/权益比FMCRPRX
| Q1 26 | 1.50× | — | ||
| Q4 25 | 1.62× | 0.92× | ||
| Q3 25 | 0.89× | 0.93× | ||
| Q2 25 | 0.76× | 0.84× | ||
| Q1 25 | 0.71× | 0.78× | ||
| Q4 24 | 0.69× | 0.74× | ||
| Q3 24 | 0.68× | 0.74× | ||
| Q2 24 | 0.68× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-628.1M | — |
| 自由现金流率自由现金流/营收 | -82.8% | — |
| 资本支出强度资本支出/营收 | 2.2% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-154.0M | — |
8季度趋势，按日历期对齐
经营现金流FMCRPRX
| Q1 26 | — | — | ||
| Q4 25 | $657.1M | $827.1M | ||
| Q3 25 | $-184.2M | $702.6M | ||
| Q2 25 | $65.9M | $364.0M | ||
| Q1 25 | $-545.0M | $596.1M | ||
| Q4 24 | $427.9M | $742.5M | ||
| Q3 24 | $159.5M | $703.6M | ||
| Q2 24 | $292.2M | $658.2M |
自由现金流FMCRPRX
| Q1 26 | $-628.1M | — | ||
| Q4 25 | $631.1M | — | ||
| Q3 25 | $-207.9M | — | ||
| Q2 25 | $50.9M | — | ||
| Q1 25 | $-576.6M | — | ||
| Q4 24 | $406.3M | — | ||
| Q3 24 | $143.8M | — | ||
| Q2 24 | $282.3M | — |
自由现金流率FMCRPRX
| Q1 26 | -82.8% | — | ||
| Q4 25 | 58.3% | — | ||
| Q3 25 | -38.3% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | -72.9% | — | ||
| Q4 24 | 33.2% | — | ||
| Q3 24 | 13.5% | — | ||
| Q2 24 | 27.2% | — |
资本支出强度FMCRPRX
| Q1 26 | 2.2% | — | ||
| Q4 25 | 2.4% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 1.0% | — |
现金转化率FMCRPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 0.99× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 2.45× | 1.29× | ||
| Q2 24 | 0.99× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FMC
| EMEA | $307.0M | 40% |
| North America | $198.0M | 26% |
| Latin America | $177.0M | 23% |
| Asia (excluding 2026 India) 1 | $81.0M | 11% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
